Form 4: Lava Therapeutics Director Acquires Options in Latest SEC Filing

Karen J. Wilson, a director of LAVA Therapeutics N.V., acquired options to purchase 33,390 common shares at $0.93 per share, according to a recent SEC Form 4 filing.

Summary

• On February 13, 2025, Karen J. Wilson, a director of LAVA Therapeutics N.V., acquired options to purchase 33,390 common shares.
• The exercise price of these options is $0.93 per share.
• The options vest on February 13, 2026, contingent upon continued service with the Issuer or its subsidiary.
• The options expire on February 12, 2035.
• Following the transaction, Wilson directly owns 33,390 common shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of an insider transaction. The acquisition of options by a director can be seen as a mildly positive signal, but it's not a strong indicator of significant positive or negative sentiment.

Positives

• A director's acquisition of options can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, common in the biopharmaceutical industry where equity compensation is frequently used.

Key Dates

Keywords

LAVA Therapeutics, Director, Options, SEC Form 4, Beneficial Ownership, LVTX, Karen J. Wilson